You just read:

ACR/ARHP 2017: Long-Term Use of Lilly's Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors

News provided by

Eli Lilly and Company

Nov 08, 2017, 08:00 EST